$RLYB
Rallybio Corp

2024 Q4 Form 10-Q Financial Statement

#000173941024000136 Filed on November 07, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue $300.0K
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.125M
YoY Change -32.15%
% of Gross Profit
Research & Development $8.240M
YoY Change -37.99%
% of Gross Profit
Depreciation & Amortization $32.00K
YoY Change 6.67%
% of Gross Profit
Operating Expenses $12.37M
YoY Change -36.14%
Operating Profit -$12.07M
YoY Change -37.69%
Interest Expense $986.0K
YoY Change -36.39%
% of Operating Profit
Other Income/Expense, Net $1.237M
YoY Change -24.43%
Pretax Income -$10.83M
YoY Change -38.91%
Income Tax
% Of Pretax Income
Net Earnings -$11.47M
YoY Change -37.6%
Net Earnings / Revenue -3822.0%
Basic Earnings Per Share -$0.26
Diluted Earnings Per Share -$0.26
COMMON SHARES
Basic Shares Outstanding 41.49M shares 41.49M shares
Diluted Shares Outstanding 44.59M shares

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $75.14M
YoY Change -38.11%
Cash & Equivalents $25.32M
Short-Term Investments $49.82M
Other Short-Term Assets $1.751M
YoY Change -51.25%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $78.23M
YoY Change -40.92%
LONG-TERM ASSETS
Property, Plant & Equipment $145.0K
YoY Change -48.58%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $431.0K
YoY Change 331.0%
Other Assets
YoY Change
Total Long-Term Assets $777.0K
YoY Change 0.65%
TOTAL ASSETS
Total Short-Term Assets $78.23M
Total Long-Term Assets $777.0K
Total Assets $79.01M
YoY Change -40.68%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $583.0K
YoY Change 25.65%
Accrued Expenses $6.279M
YoY Change -28.0%
Deferred Revenue $1.097M
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $8.189M
YoY Change -12.9%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities $0.00
YoY Change -100.0%
Total Long-Term Liabilities $0.00
YoY Change -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $8.189M
Total Long-Term Liabilities $0.00
Total Liabilities $8.189M
YoY Change -14.81%
SHAREHOLDERS EQUITY
Retained Earnings -$282.0M
YoY Change 31.15%
Common Stock $4.000K
YoY Change 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $70.82M
YoY Change
Total Liabilities & Shareholders Equity $79.01M
YoY Change -40.68%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income -$11.47M
YoY Change -37.6%
Depreciation, Depletion And Amortization $32.00K
YoY Change 6.67%
Cash From Operating Activities -$13.55M
YoY Change -17.76%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $22.21M
YoY Change 623.29%
Cash From Investing Activities $22.21M
YoY Change 623.29%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -11.00K
YoY Change
NET CHANGE
Cash From Operating Activities -13.55M
Cash From Investing Activities 22.21M
Cash From Financing Activities -11.00K
Net Change In Cash 8.649M
YoY Change -164.54%
FREE CASH FLOW
Cash From Operating Activities -$13.55M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Entity File Number
EntityFileNumber
001-40693
dei Entity Registrant Name
EntityRegistrantName
RALLYBIO CORPORATION
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
24494000 usd
CY2023Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
85435000 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4860000 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
114789000 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
246000 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
346000 usd
CY2023Q4 us-gaap Investments In Affiliates Subsidiaries Associates And Joint Ventures
InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
239000 usd
CY2023Q4 us-gaap Assets
Assets
115620000 usd
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
219000 usd
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
8189000 usd
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0 usd
CY2024Q3 us-gaap Liabilities
Liabilities
8189000 usd
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
352621000 usd
CY2024Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
169000 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-281976000 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
70818000 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
70818000 usd
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
41487586 shares
dei Document Type
DocumentType
10-Q
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 1020
dei Entity Address City Or Town
EntityAddressCityOrTown
New Haven
dei Entity Address State Or Province
EntityAddressStateOrProvince
CT
dei Trading Symbol
TradingSymbol
RLYB
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
230000 usd
CY2024Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
1097000 usd
CY2023Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
0 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
9263000 usd
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
173000 usd
us-gaap Revenues
Revenues
598000 usd
us-gaap Interest And Other Income
InterestAndOtherIncome
4699000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
561000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
227000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3966000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-44922000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-52894000 usd
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.45
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.35
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.35
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.45
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
123581000 usd
dei Entity Central Index Key
EntityCentralIndexKey
0001739410
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
85-1083789
dei Entity Address Address Line1
EntityAddressAddressLine1
234 Church Street
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
06510
dei City Area Code
CityAreaCode
203
dei Local Phone Number
LocalPhoneNumber
859-3820
dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
dei Entity Bankruptcy Proceedings Reporting Current
EntityBankruptcyProceedingsReportingCurrent
true
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
41487586 shares
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
25320000 usd
CY2024Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
49819000 usd
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3091000 usd
CY2024Q3 us-gaap Assets Current
AssetsCurrent
78230000 usd
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
145000 usd
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
201000 usd
CY2024Q3 us-gaap Investments In Affiliates Subsidiaries Associates And Joint Ventures
InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
431000 usd
CY2024Q3 us-gaap Assets
Assets
79007000 usd
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
583000 usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
976000 usd
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6279000 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8068000 usd
CY2023Q4 us-gaap Liabilities
Liabilities
9436000 usd
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
41487586 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
37829565 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
37829565 shares
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
4000 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
4000 usd
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000 shares
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000 shares
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2024Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
341410000 usd
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
15000 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-235245000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
106184000 usd
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
79007000 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
115620000 usd
CY2024Q3 us-gaap Revenues
Revenues
299000 usd
CY2023Q3 us-gaap Revenues
Revenues
0 usd
us-gaap Revenues
Revenues
0 usd
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8240000 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13288000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
34122000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
37620000 usd
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4125000 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6075000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
15364000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
20200000 usd
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
12365000 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
19363000 usd
us-gaap Operating Expenses
OperatingExpenses
49486000 usd
us-gaap Operating Expenses
OperatingExpenses
57820000 usd
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-12066000 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-19363000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-48888000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-57820000 usd
CY2024Q3 us-gaap Interest And Other Income
InterestAndOtherIncome
986000 usd
CY2023Q3 us-gaap Interest And Other Income
InterestAndOtherIncome
1545000 usd
us-gaap Interest And Other Income
InterestAndOtherIncome
3405000 usd
CY2024Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
251000 usd
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
92000 usd
CY2024Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1237000 usd
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1637000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
4926000 usd
CY2024Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-10829000 usd
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-17726000 usd
CY2024Q3 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-637000 usd
CY2023Q3 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-648000 usd
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-1809000 usd
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-1428000 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-11466000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-18374000 usd
us-gaap Net Income Loss
NetIncomeLoss
-46731000 usd
us-gaap Net Income Loss
NetIncomeLoss
-54322000 usd
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.26
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.26
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.08
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.08
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
44593221 shares
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
44593221 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
40531497 shares
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
40531497 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
43170177 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
43170177 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
40382625 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
40382625 shares
CY2024Q3 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
240000 usd
CY2023Q3 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
64000 usd
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
154000 usd
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
6000 usd
CY2024Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
240000 usd
CY2023Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
64000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
154000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
6000 usd
CY2024Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-11226000 usd
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-18310000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-46577000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-54316000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
139257000 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2634000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-18374000 usd
CY2023Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
64000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
123581000 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
80017000 usd
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2027000 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-11466000 usd
CY2024Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
240000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
169317000 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8371000 usd
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
209000 usd
us-gaap Net Income Loss
NetIncomeLoss
-54322000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
6000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
106184000 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6030000 usd
rlyb Securities Purchase Agreement Offering Costs
SecuritiesPurchaseAgreementOfferingCosts
268000 usd
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
5137000 usd
rlyb Stock Issued During Period Value Vested
StockIssuedDuringPeriodValueVested
0 usd
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
44000 usd
us-gaap Net Income Loss
NetIncomeLoss
-46731000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
154000 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
70818000 usd
us-gaap Net Income Loss
NetIncomeLoss
-46731000 usd
us-gaap Net Income Loss
NetIncomeLoss
-54322000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
101000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
114000 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
-1296000 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
-2432000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
6030000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
8371000 usd
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-1809000 usd
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-1428000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1914000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
400000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-393000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-623000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1951000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-756000 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
1097000 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
0 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-39420000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-48620000 usd
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
31609000 usd
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
95675000 usd
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
68674000 usd
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
107924000 usd
us-gaap Payments To Acquire Interest In Joint Venture
PaymentsToAcquireInterestInJointVenture
2000000 usd
us-gaap Payments To Acquire Interest In Joint Venture
PaymentsToAcquireInterestInJointVenture
1500000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
35065000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
10749000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
5405000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 usd
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
44000 usd
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
209000 usd
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
268000 usd
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
138000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
5181000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
71000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
826000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-37800000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
24494000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
56958000 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
25320000 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
19158000 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
0 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
12000 usd
CY2024Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
75100000 usd
CY2024Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
68529000 usd
CY2024Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
170000 usd
CY2024Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
1000 usd
CY2024Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
68698000 usd
CY2023Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
101948000 usd
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
79000 usd
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
64000 usd
CY2023Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
101963000 usd
CY2024Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
68698000 usd
CY2023Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
101963000 usd
CY2024Q3 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
62297000 usd
CY2023Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
98110000 usd
CY2024Q3 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
6401000 usd
CY2023Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
3853000 usd
CY2024Q3 us-gaap Available For Sale Securities Debt Maturities Single Maturity Date
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate
68698000 usd
CY2023Q4 us-gaap Available For Sale Securities Debt Maturities Single Maturity Date
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate
101963000 usd
CY2024Q3 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
2000000.0 usd
CY2023Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
40000000.0 usd
CY2023Q4 us-gaap Financing Receivable Allowance For Credit Losses
FinancingReceivableAllowanceForCreditLosses
0 usd
CY2024Q3 us-gaap Financing Receivable Allowance For Credit Losses
FinancingReceivableAllowanceForCreditLosses
0 usd
CY2024Q3 rlyb Prepaid Research And Development Expenses
PrepaidResearchAndDevelopmentExpenses
446000 usd
CY2023Q4 rlyb Prepaid Research And Development Expenses
PrepaidResearchAndDevelopmentExpenses
2067000 usd
CY2024Q3 us-gaap Prepaid Insurance
PrepaidInsurance
608000 usd
CY2023Q4 us-gaap Prepaid Insurance
PrepaidInsurance
446000 usd
CY2024Q3 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
286000 usd
CY2023Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
293000 usd
CY2024Q3 us-gaap Other Assets Current
OtherAssetsCurrent
1751000 usd
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
2054000 usd
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3091000 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4860000 usd
CY2024Q3 rlyb Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
3218000 usd
CY2023Q4 rlyb Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
4123000 usd
CY2024Q3 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
2420000 usd
CY2023Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
3166000 usd
CY2024Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
430000 usd
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
332000 usd
CY2024Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
211000 usd
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
447000 usd
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6279000 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8068000 usd
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
41487586 shares
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
41487586 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
37829565 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
37829565 shares
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000 shares
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000 shares
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2027000 usd
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2634000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6030000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8371000 usd
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4270544 shares
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
9.98
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y6M
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1119039 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.89
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
629829 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
9.19
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
25950 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
12.32
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4733804 shares
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.16
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y4M24D
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0 usd
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2551303 shares
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
10.10
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y4M24D
CY2024Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
0 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.47
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.93
CY2024Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
9300000 usd
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y1M6D
CY2023Q4 rlyb Termination Charges
TerminationCharges
0 usd
CY2024Q3 rlyb Termination Charges
TerminationCharges
0 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-11466000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-18374000 usd
us-gaap Net Income Loss
NetIncomeLoss
-46731000 usd
us-gaap Net Income Loss
NetIncomeLoss
-54322000 usd
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
44593221 shares
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
44593221 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
40531497 shares
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
40531497 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
43170177 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
43170177 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
40382625 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
40382625 shares
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.26
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.26
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.45
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.45
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.08
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.08
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.35
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.35
CY2024Q1 us-gaap Restructuring And Related Cost Number Of Positions Eliminated Period Percent
RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
0.45
CY2024Q1 us-gaap Restructuring And Related Cost Expected Cost1
RestructuringAndRelatedCostExpectedCost1
3300000 usd
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Revenues
Revenues
300000 usd
us-gaap Revenues
Revenues
600000 usd
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001739410-24-000136-index-headers.html Edgar Link pending
0001739410-24-000136-index.html Edgar Link pending
0001739410-24-000136.txt Edgar Link pending
0001739410-24-000136-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
rlyb-20240930.htm Edgar Link pending
rlyb-20240930.xsd Edgar Link pending
rlyb-20240930xex311.htm Edgar Link pending
rlyb-20240930xex312.htm Edgar Link pending
rlyb-20240930xex321.htm Edgar Link pending
rlyb-20240930xex322.htm Edgar Link pending
rlyb-20240930_g1.jpg Edgar Link pending
Show.js Edgar Link pending
rlyb-20240930_def.xml Edgar Link unprocessable
rlyb-20240930_cal.xml Edgar Link unprocessable
rlyb-20240930_lab.xml Edgar Link unprocessable
rlyb-20240930_pre.xml Edgar Link unprocessable
rlyb-20240930_htm.xml Edgar Link completed